|
Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer Clinical research trials and Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer. Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer  Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer
Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer
For Condition: Breast Cancer
Status: Completed
Sponsor(s): University of Kansas , National Cancer Institute (NCI)
Synopsis: RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Indole-3-carbinol may be effective in preventing breast cancer. PURPOSE: Phase I trial to study the effectiveness of indole-3-carbinol in preventing breast cancer in nonsmoking women who are at high risk for breast cancer.
Details: OBJECTIVES: - Determine the safety and tolerability of indole-3-carbinol for the prevention of breast cancer in non-smoking women at high risk for breast cancer. - Determine the pharmacokinetics of this drug in these participants. - Determine the effect of this drug on metabolites of estrogen in urine of these participants. - Determine other additional effects of this drug on selected indicators of drug metabolism and reproductive and hormonal function in these participants. - Assess any possible antineoplastic activity of this drug in these participants. - Determine the quality of life of participants receiving this drug. OUTLINE: This is a single-blind study. Participants ingest study compound twice daily on weeks 1-12 or 1-16. Study compound is dispensed on weeks 1, 5, and 9. At times, study compound is oral placebo, and at other times, oral indole-3-carbinol. Quality of life is assessed at baseline and then every 4 weeks during study therapy. PROJECTED ACCRUAL: A total of 18 participants will be accrued for this study within 9 months.
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: 18 Years/70 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Women at high risk for breast cancer, defined by at least 1 of the following criteria: - Projected 5-year probability of invasive breast cancer at least 1.66%, as determined by the Breast Cancer Risk Assessment Tool - Prior node-negative breast cancer - Prior biopsy indicating atypical lobular or ductal hyperplasia or carcinoma in situ - Age 60 and over - Non-smoker confirmed by urine cotinine test - No concurrent breast cancer - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 to 70 Sex: - Female Menopausal status: - Premenopausal (regular menstrual cycles of 24-36 days within the past 6 months) OR - Postmenopausal (no menstrual cycle for at least 6 months) Performance status: - Not specified Life expectancy: - At least 1 year Hematopoietic: - Absolute granulocyte count greater than 1,500/mm^3 - Hemoglobin greater than 10 g/dL Hepatic: - Bilirubin less than 1.8 mg/dL - AST and ALT less than 110 U/L - Alkaline phosphatase less than 300 U/L - Albumin greater than 3 g/dL Renal: - Creatinine less than 2.0 mg/dL Cardiovascular: - No acute or unstable cardiovascular condition based on electrocardiogram Other: - Mild seasonal allergies allowed - No serious or life-threatening drug allergies - No other serious intolerances or allergies - No more than 20% above or below ideal body weight - No acute or unstable medical condition by physical examination or laboratory tests - No chronic headaches, dysphoria, fatigue, dizziness, blurred vision, insomnia, rhinorrhea, nausea, vomiting, abdominal pain, diarrhea, constipation, or similar conditions - No serious illness requiring chronic drug therapy - No active malignancy - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception 1 month before, during, and for 1 month after study PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior chemotherapy Endocrine therapy: - At least 2 months since prior hormonal therapy as contraception or hormone replacement therapy (HRT) - No concurrent sex hormones as contraception for premenopausal women - No concurrent HRT for postmenopausal women Radiotherapy: - Not specified Surgery: - Not specified Other: - At least 6 months since prior investigational drugs - At least 1 month since prior weekly consumption of more than 3 medium servings (half cup each) of cruciferous vegetables - No concurrent vegetarian diet or weekly consumption of more than 3 medium servings (half cup each) of cruciferous vegetables - No continuous supplement intake - No recent change in medications or dosage of medications
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AryehHurwitz, Study Chair, University of Kansas
University of Kansas Medical Center
Kansas City, Kansas, 66160-7320
United States
Additional Information:
Study ID Numbers: CDR0000069276; KUMC-8508-01,NCI-P02-0217
Study Start Date:
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00033345
Other Breast Cancer Studies:
1. p53 Peptide vaccination for Breast or Ovary Cancer
2. Docetaxel and Flavopiridol to Treat Breast Cancer
3. Study of Etoposide in Breast Cancer Patients
4. A Dose-Escalation Vaccine Trial In HER2-Overexpressing Patients With High-Risk Breast Cancer
5. Irinotecan and Capecitabine in Treating Patients With Solid Tumors
Related Studies:
Other Breast Cancer Clinical Trials
Other Kansas Clinical Trials
Other Kansas City Clinical Trials
Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer
|
|
|
|
|
|
|
|
